Nucleotide prodrug compounds
Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.
1. A compound of Formula I:
wherein:
R 1 is selected from the group consisting of H, an optionally substituted C 1 -C 15 alkyl, an optionally substituted C 3 -C 15 cycloalkyl, and an optionally substituted C 2 -C 15 alkenyl;
R 2 is selected from the group consisting of halogen, an optionally substituted alkyl, and an optionally substituted alkyloxy;
R 3 is selected from the group consisting of H, an optionally substituted acyl, and C-carboxy;
R 4 is selected from the group consisting of H, an optionally substituted acyl, C-amido, and C-carboxy; and
n is 0, 1, 2, or 3;
or a stereoisomer or pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein n is 1.
3. The compound of claim 1 , wherein n is 0.
4. The compound of claim 1 , wherein R 3 is H.
5. The compound of claim 1 , wherein R 1 is an optionally substituted C 1 -C 15 alkyl.
6. The compound of claim 5 , wherein R 1 is an unsubstituted C 1 -C 6 alkyl.
7. The compound of claim 6 , wherein R 1 is ethyl.
8. The compound of claim 6 , wherein R 1 is n-propyl.
9. The compound of claim 6 , wherein R 1 is i-propyl.
10. The compound of claim 6 , wherein R 1 is methyl.
11. The compound of claim 1 , wherein R 4 is C-carboxy.
12. The compound of claim 1 , wherein R 4 is acyl.
13. The compound of claim 1 , wherein the compound is selected from the group consisting of:
14. A method of treating a viral infection comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.
15. The method of claim 14 , wherein the subject is a mammal.
16. The method of claim 15 , wherein the mammal is a human.
17. The method of claim 14 , further comprising administering one or more additional therapeutic agents.